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Abstract
Purpose Dronedarone is a benzofuran derivative with a phar-
macological profile similar to amiodarone but has a more
rapid onset of action and a much shorter half-life (13–19 h).
Our goal was to evaluate the efficacy of dronedarone in atrial
fibrillation (AF) patients using dual-chamber pacemakers ca-
pable of quantifying atrial fibrillation burden.
Methods Pacemakers were adjusted to optimize AF detection.
Patients with AF burden >1 % were randomized to
dronedarone 400 mg twice daily (BID) or placebo. Pace-
makers were interrogated after 4 and 12 weeks of treatment.
The primary endpoint was the change in AF burden from
baseline over the 12-week treatment period. Patients with
permanent AF, severe/recently decompensated heart failure,
and current use of antiarrhythmic drugs were excluded. AF
burden was assessed by a core laboratory blinded to treatment
assignment.
Results From 285 patients screened, 112 were randomized
(mean age 76 years, 60 % male, 84 % hypertensive, 65 %
with sick sinus syndrome, 26 % with diabetes mellitus type II,
15 % with heart failure). Baseline mean (SEM) AF burden
was 8.77 % (0.16) for placebo and 10.14 % (0.17) for
dronedarone. Over the 12-week study period, AF burden
compared to baseline decreased by 54.4 % (0.22) (P=
0.0009) with dronedarone and trended higher by 12.8 %
(0.16) (P=0.450) with placebo. The absolute change in bur-
den was decreased by 5.5 % in the dronedarone group and
increased by 1.1 % in the placebo group. Heart rate during AF
was reduced to approximately 4 beats/min with dronedarone
(P=0.285). Adverse events were higher with dronedarone
compared to placebo (65 vs 56 %).
Conclusions Dronedarone reduced pacemaker-assessed the
relative AF burden compared to baseline and placebo by over
50 % during the 12-week observation period.
Keywords Atrial fibrillation . Dronedarone . Pacemaker .
Burden
1 Introduction
There is a need to develop safe and effective antiarrhythmic
agents for the treatment of atrial fibrillation (AF) [1].
Dronedarone HCl, a benzofuran derivative with a pharmaco-
logic profile similar to amiodarone [2–5], was approved by the
Food and Drug Administration in 2009. In the USA, it is
indicated to reduce the risk of hospitalization for AF in pa-
tients in sinus rhythm with a history of paroxysmal or persis-
tent AF [6]. Results from key trials involving nearly 6000
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patients demonstrated that dronedarone reduces AF recur-
rence and the composite of CV hospitalization and death in
non-permanent AF [7, 8]. Dronedarone possesses all four
Vaughan-Williams antiarrhythmic properties, with blockade
of sodium channels, noncompetitive antiadrenergic activity,
prolongation of the action potential and refractory periods,
and calcium antagonist properties [2, 5, 6]. Compared to
amiodarone, dronedarone lacks iodine, is less lipophilic, and
has a shorter half-life (13–19 h vs ~58 days for amiodarone),
thereby decreasing accumulation in tissue [5, 6, 9].
Dronedarone has a low systemic bioavailability, which in-
creases up to 15 % when the drug is administered after a fatty
meal. After repeated administration of 400 mg twice daily
(BID), steady state is reached within 4 to 8 days [6, 10].
Dronedarone is metabolized by CYP3A enzyme system [6,
10].
The efficacy of antiarrhythmic drugs in patients with AF
has been tested using the time to first recurrence of symptom-
atic AF [11–14]; AF events, however, frequently occur in
clusters, thus questioning the validity of this endpoint
[15–17]. In addition, time to first recurrence data fail to
quantify AF burden (i.e., percent of time in AF), frequency,
and number of episodes [12], all of which may carry a differ-
ent prognosis. Asymptomatic episodes are common and com-
plicate the assessment and may in fact represent the majority
of AF episodes and may be associated with mortality and
stroke risk [18, 19]. The availability of continuous monitoring
permits documentation of frequency, duration, time of onset,
and rate of AF as well as AF burden [17, 20, 21]. Patients with
accepted indications for permanent pacemakers, particularly
patients with sinus node disease, are at significant risk for AF,
with prevalence rates of up to and over 50 % in some studies
[22–24]. The Effects of Dronedarone on Atrial Fibrillation
Burden in Subjects with Permanent Pacemakers (HESTIA;
ClinicalTrials.gov number, NCT01135017) evaluates the im-
pact of dronedarone on AF burden in patients with AF and
permanent cardiac pacemakers.
2 Methods
The intent of HESTIAwas to enroll 290 AF patients with an
interim analysis when 150 patients completed. Recruitment
was slow and the study was terminated after enrollment of 112
patients. For entry, patients had to be at least 21 years of age
with documented AF and sinus rhythm within the previous
6 months. Patients were included if one of the following CV
risk factors were present: age ≥70 years, hypertension, diabe-
tes mellitus, prior CV accident (stroke or transient ischemic
attack) or systemic embolism, or M-mode or 2D echocardi-
ography findings showing a left atrium diameter ≥50 mm or
left ventricular ejection fraction less than ≤0.40 within the
prior 12 months.
HESTIA was a placebo-controlled, double-blind, random-
ized, multicenter trial designed to assess the effects of
dronedarone 400 mg BID versus placebo on AF burden in
patients with a permanent pacemaker. Following patient con-
sent, pacemakers were programmed to optimize atrial sensing.
First, far-field R wave oversensing at maximum atrial sensi-
tivity was assessed both during ventricular pacing and during
ventricular sensing (if feasible). If far-field R wave
oversensing was present, post-ventricular atrial blanking peri-
od (PVAB) was increased 25 ms beyond the longest far-field
R wave signal. If there was no far-field R wave oversensing,
PVAB was programmed to nominal setting. Final atrial sensi-
tivity was set between 0.25 to 0.35 mV or above if needed
(minimum allowable sensitivity was 0.75 mV). Patients were
excluded if atrial sensing was <1 mV. The pacemakers were
programmed to DDD or MVP mode and ventricular sensing
was promoted by programming long AV delay if intrinsic
conduction allowed. Mode switch rate was set to 200 bpm
and the maximum number of bipolar atrial electrograms
(EGMs) was stored for these episodes in the pacemakers.
EGMs were reviewed as a quality control measure to ensure
that they were due to atrial arrhythmias and that mode
switches were accurate. Atrial overdrive pacing or atrial tachy-
cardia therapies were programmed off. The study was con-
ducted with support of a Pacemaker Core Laboratory (PER-
FUSE, Boston, MA) to ensure quality control. The core lab-
oratory reviewed all interrogation reports and electrograms to
ensure that pacemaker settings were consistent with protocol
requirements and that pacemakers were accurately recording
AF (i.e., atrial high rate episodes).
Patients were allowed treatment with concomitant medica-
tions based on dronedarone prescribing recommendations.
Where possible, digoxin was either discontinued or halved.
Treatment with Vaughan-Williams class I and III antiarrhyth-
mics was prohibited. Use of amiodarone was prohibited with-
in 4 weeks of screening.
Patients were randomized 1:1 to dronedarone or placebo
and treated for 12 weeks. The trial was conducted in accor-
dance with all applicable ethical and good clinical practice
principles, including the Declaration of Helsinki. Written in-
formed consent was obtained from all participants.
All subjects had a dual-chamber pacemaker placed for an
approved clinical indication from which AF burden was de-
termined. There was an initial 4-week screening period
(Fig. 1). AF burden was defined as arrhythmia time/24 h
(e.g., 6 h of AF arrhythmia time would be 25 %). The AF
burden had to be at least 1 % during the 4-week screening
period off anti-arrhythmic therapy for study eligibility. For
eligible patients, the AF burden during the screening period
constituted the baseline AF burden. Pacemaker interrogations
were also performed at 4 and 12 weeks after randomization. A
final follow-up visit was performed 14 weeks after
randomization.
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The primary objective of this study was the effect of
dronedarone on AF burden. Secondary objectives included
the effects of dronedarone on ventricular rate during AF;
patient-perceived AF burden; and symptom severity as report-
ed by patients using the Atrial Fibrillation Severity Scale
(AFSS). The number of electrical cardioversions and manual
overdrive pacing events during treatment were collected.
An independent Data Monitoring Committee monitored
safety, deaths, hospitalizations, and adverse events leading to
drug discontinuation. Areas of special interest were conges-
tive heart failure (CHF), diagnosis of interstitial lung disease,
skin disorders, and peripheral neuropathy, the latter three are
well known complications of amiodarone. CHF was assessed
at screening and throughout the study. The planned sample
size of 290 was estimated to have 70 % power to detect a
reduction in mean AF burden of 30 % relative to the placebo
group. The early termination of the study at 112 patients
randomized reduced the power to detect treatment effects to
under 50 %. The modified intent-to-treat (mITT) population
included all patients who were randomized, treated with ≥1
dose of dronedarone, and had ≥1 post-baseline assessment of
AF burden. The safety population was defined as the random-
ized population who received ≥1 dose of study medication.
AF burden during the 12-week treatment period was analyzed
in log-scale with adjustment for the baseline to compare AF
burden between the dronedarone and placebo arms due to the
non-normal distribution of AF burden. An analysis of covari-
ance (ANCOVA) model was applied to the log-transformed
AF burden data. The difference between treatment arms was
estimated by the least squares mean method and was signifi-
cant if the two-sided p value of the test was <0.05.
For secondary efficacy analyses, AF burden in the first
4 weeks and after 4 weeks of treatment was analyzed using
the statistical method described for the primary efficacy var-
iable and the average ventricular rate during AF episodes and
the Atrial Fibrillation Severity Scale (AFSS) scores were
analyzed without transformation using an ANCOVA model
with treatment arm as a fixed effect term and the baseline
value as a covariate. Electrical cardioversion (or overdrive
pacing) was recorded.
3 Results
Two hundred and eighty-five subjects were screened; 112
(Fig. 2 and Table 1) were randomized to receive treatment.
Cardiovascular history of randomized subjects included hy-
pertension in 84 %, sick sinus syndrome in 65 %, and con-
gestive heart failure in 15 % of patients (Table 2). At random-
ization, 82 % were prescribed rate-lowering medications and
73 % oral anticoagulants (Table 3). Two subjects did not have
a post-randomization interrogation of their pacemaker. Both
were excluded from the primary efficacy analysis.
Median duration of treatment was 12 weeks. Ninety-four
subjects completed the study, and 18 subjects discontinued
treatment due to the investigator’s or subject’s decision. Dis-
continuations due to an adverse event in the dronedarone
group (14 %) exceeded those in the placebo group (6 %).
Over the 12-week treatment period, mean AF burden in-
creased from 8.8 % (0.16) to 9.9 % (0.20) (increase of 12.8 %
(0.16); P=0.450) in the placebo group and decreased from
10.1 % (0.17) to 4.6 % (0.29) (decrease of 54.4 % (0.22); P=
0.0009) in the dronedarone group. The absolute changes in AF
burden from baseline increased by 1.1 % in the placebo group
and decreased by 5.5% in the dronedarone group. Compared to
placebo, AF burden in the dronedarone groupwas decreased by
59.1 % (0.28 %) (P=0.0015; Fig. 3). AF burden changes with
dronedarone compared to placebo in secondary efficacy analy-
ses were consistent with the overall result (weeks 1–4, 63.2 %
(0.29) reduction, P=0.0009; weeks 5–12, 60.3 % (0.30) reduc-
tion, P=0.003). The distribution of baseline versus weeks 1–12
AF burden in treated patients is shown in Fig. 4.
The mean ventricular rate during AF was approximately
4 bpm lower in the dronedarone treatment group compared to
placebo (P=0.285). AFSS changes from baseline were not
significantly different between groups (Table 4). Only one
patient in the placebo group was cardioverted.
Treatment-emergent adverse events were common in both
groups (dronedarone, 64.9 %; placebo, 56.4 %); most were
gastrointestinal (Table 5). Treatment-emergent serious adverse
events occurred in 14 patients (7 in each treatment group).
Serious adverse events in the dronedarone group included
Fig. 1 Trial design. AF atrial
fibrillation, BID twice daily, EGM
electrogram, PPM permanent
pacemaker
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congestive heart failure, peripheral neuropathy, ocular dis-
comfort, presyncope, muscle rupture, and cardiomyopathy.
More patients in the dronedarone group discontinued treat-
ment due to adverse events compared with placebo (8
[14.0 %] vs 3 [5.5 %], respectively). There was no evidence
of dronedarone-induced ventricular tachycardia and there
were no deaths, strokes, or major bleeding events in the study.
4 Discussion
The major finding was a 59% relative reduction of AF burden
with dronedarone compared to placebo (P=0.0015). In the
placebo group, the mean (geometric) AF burden increased
from 8.8 to 9.9 % during the treatment period, whereas in
the dronedarone group, the mean (geometric) AF burden was
decreased from 10.1 to 4.6 %, an absolute reduction of 5.5 %.
The effect was consistent over the 12-week duration of treat-
ment. Average ventricular rate during AF was slightly (4 bpm)
lower in the dronedarone group, but these differences were not
statistically significant. There were no statistically significant
differences in the AFSS. One patient was cardioverted.
Consistent with the known profile of dronedarone, there
was an increase in gastrointestinal events. Serious adverse
events and discontinuations due to adverse events were infre-
quent but occurred more often in the dronedarone group.
There were no deaths in the study.
Two large multicenter, randomized, placebo-controlled
studies evaluated the efficacy of dronedarone on AF recur-
rence [7, 8]. In the pooled analysis of the European Trial in
Atrial Fibrillation or Flutter Patients Receiving Dronedarone
for the Maintenance of Sinus Rhythm (EURIDIS,
NCT00259428) and the American-Australian-African Trial
with Dronedarone in Atrial Fibrillation or Flutter Patients for
t he Ma in t enance o f S inus Rhy thm (ADONIS ,
NCT00259376), dronedarone significantly delayed the time
to first recurrence of AF during the 12-month study period by
approximately 25 % (P<0.001 vs placebo), with an absolute
difference in recurrence rate of ~11 % [8].
Use of pacemaker determined AF burden has been the
subject of several prior studies and has potentially important
clinical implications. A recent trial of patients with bradycar-
dia and a history of AF receiving pacemakers indicated that
total AF burden had a significant but weak correlation with
cardiac hospitalization rates [25]. Although total AF burden is
typically used as an endpoint in device trials such as the Atrial
Therapy Efficacy and Safety Trial (ATTEST) [21, 26–29], it
may also be a useful endpoint for antiarrhythmic medications.
Table 1 Patient baseline demographics
Placebo
(n=55)
Dronedarone
(n=57)
All
(N=112)
Age, mean (SD), years 74.5 (9.5) 77.3 (8.6) 75.9
(9.1)
Men, n (%) 38 (69.1) 29 (50.9) 67 (59.8)
Hispanic, n (%) 0 1 (1.8) 1 (0.9)
Race, n (%)
Caucasian/White 50 (90.9) 54 (94.7) 104
(92.9)
Black 5 (9.1) 2 (3.5) 7 (6.3)
Asian/Oriental 0 1 (1.8) 1 (0.9)
Body mass index ≥30 kg/m2 24 (43.6) 22 (38.6) 46 (41.1)
Creatinine clearance, mean
(SD), mL/min
73.2 (27.2) 66.1 (31.4) 69.6
(29.5)
SD standard deviation
Fig. 2 Patient disposition at end
of study. AFB atrial fibrillation
burden, D/C discontinuation, ITT
intent to treat
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The Paroxysmal Atrial Fibrillation Study with Continuous
Atrial Fibrillation Logging (PASCAL, NCT00389792) trial
found up to a 74 % reduction in AF burden with budiodarone
in an investigational dose ranging study [17].
The study had several limitations. First, study enrollment
was below goals (290 planned vs 112 actual patients with
interim analysis planned at 150 patients) because of the diffi-
culty in finding non-permanent AF patients with at least 1 %
AF burden on initial screening and during the 4-week baseline
period. The study, however, was analyzed as originally
planned with the primary endpoint achieving a highly signif-
icant (P=0.0015) outcome. A second limitation is the use of
mode switches to assess AF burden with the risks of under or
oversensing. Efforts were made to mitigate this risk including
use of a pacemaker core lab to ensure that pacemakers were
appropriately set to study requirements and that pacemakers
were accurately recording AF. Last, because HESTIA was
placebo-controlled, patients with more severe AF symptoms
were excluded. Low baseline AFSS burden and symptom
scores reflect this and may have mitigated finding significant
changes in the AFSS despite significant reductions in AF
burden observed in the study.
Table 2 Cardiovascular history of randomized patients
Placebo
(n=55)
Dronedarone
(n=57)
All
(N=112)
Hypertension 45 (81.8)
49
(86.0)
94 (83.9)
Sick sinus syndrome 37 (67.3)
36
(63.2)
73 (65.2)
Coronary artery disease 24 (43.6)
16
(28.1)
40 (35.7)
Syncope 15 (27.3)
20
(35.1)
35 (31.3)
Atrioventricular block above first
degree
13 (23.6)
9
(15.8)
22 (19.6)
Congestive heart failure 6 (10.9) 11 (19.3) 17
(15.2)
Non-rheumatic valvular heart disease 7 (12.7) 9 (15.8) 16
(14.3)
Myocardial infarction 9 (16.4) 6 (10.5) 15
(13.4)
Ischemic stroke 6 (10.9) 5 (8.8) 11 (9.8)
Peripheral arterial disease 7 (12.7) 3 (5.3) 10 (8.9)
Transient ischemic attack 5 (9.1) 3 (5.3) 8 (7.1)
Supra-ventricular tachycardia other
than atrial fibrillation/atrial flutter
3 (5.5) 4 (7.0) 7 (6.3)
Deep vein thrombosis 3 (5.5) 3 (5.3) 6 (5.4)
Stroke of unknown origin 1 (1.8) 4 (7.0) 5 (4.5)
Ischemic dilated cardiomyopathy 2 (3.6) 2 (3.5) 4 (3.6)
Torsades de pointe 1 (1.8) 0 1 (0.9)
Ventricular fibrillation 1 (1.8) 0 1 (0.9)
All data are expressed as n (%)
Table 3 Summary of baseline medications
Placebo
(n=55)
Dronedarone
(n=57)
All
(N=112)
Beta blocking agents (except sotalol) 35 (63.6) 40
(70.2)
75 (67.0)
Angiotensin-converting enzyme
inhibitors or angiotensin II
receptor antagonists
33 (60.0) 24
(42.1)
57 (50.9)
Oral anticoagulant 38 (69.1) 44
(77.2)
82 (73.2)
Diuretics 25 (45.5) 21
(36.8)
46 (41.1)
Aspirin 26 (47.3) 19
(33.3)
45 (40.2)
Statins 34 (61.8) 32
(56.1)
66 (58.9)
Calcium antagonists with heart rate
lowering effects
12 (21.8) 8 (14.0)
20 (17.9)
Digitalis 12 (21.8) 10
(17.5)
22 (19.6)
Other chronic antiplatelet therapy 10 (18.2) 5 (8.8)
15 (13.4)
All data are expressed as n (%)
Fig. 3 Baseline (week −4 to randomization), week 4, and week 12 (end
of treatment) mean geometric AF burden. The primary efficacy result was
the least mean square (LMS) difference in AF burden between placebo
and dronedarone at week 12 (59.13 (0.28); P=0.0015. Similar results
were observed at week 4
J Interv Card Electrophysiol (2015) 42:69–76 73
The HESTIA study has important implications on design
of future trials of antiarrhythmic drugs for AF. A post hoc
calculation of study power based on our study findings was
>95 %, underscoring the sensitivity of continuous ECG mon-
itoring for assessing AF. In comparison, the EURIDIS and
ADONIS studies required >500 patients each to detect a 25 %
reduction in the rate of AF recurrence (at 12 months) with
dronedarone compared to placebo with 90 % power. Contin-
uous ECG monitoring also provides a more complete charac-
terization of AF patterns compared with traditional time to
first recurrence assessments, and also offers a sensitive meth-
od of detecting ventricular arrhythmias.
5 Conclusion
The HESTIA study was designed to investigate the effects of
dronedarone on AF burden in a population of patients
experiencing intermittent episodes of AF. Prior to randomiza-
tion, these patients were in AF an average of 10 % of the time.
Dronedarone reduced the primary endpoint, time in AF, by
slightly more than half (P<0.005). This effect was consistent
Fig. 4 Plot of AF burden at baseline versus AF burden weeks 1–12.
Points above the line represent increases in AF burden post-baseline and
points below represent reductions in AF burden. Placebo is represented as
red circles and dronedarone as black squares
Table 4 Summary of Atrial Fibrillation Severity Scale (AFSS)
Placebo
(N=55)
Dronedarone
(N=55)
AF burden
Baseline mean (SD) 13.72 (4.59) 12.76 (4.62)
Post-baseline mean (SD) 13.30 (5.40) 12.48 (5.45)
Change from baseline, mean
(SD)
−1.04 (3.22) −0.68 (4.71)
Treatment difference, LS mean
(SE)a
0.14 (0.981)
P value 0.8902
AF symptoms
Baseline mean (SD) 8.47 (6.97) 8.36 (6.83)
Post-baseline mean (SD) 8.06 (7.11) 7.42 (7.48)
Change from baseline, mean
(SD)
−0.28 (4.88) −0.72 (5.66)
Treatment difference, LS mean
(SE)a
−0.49 (0.980)
P value 0.6216
a From ANCOVA model
Table 5 Treatment-emergent adverse events
Placebo
(n=55)
Dronedarone
(n=57)
Overview of treatment-emergent
adverse events
Patients with any treatment-
emergent adverse event
31 (56.4) 37 (64.9)
Patients with any treatment-
emergent serious adverse event
7 (12.7) 7 (12.3)
Patients with any treatment-emergent
adverse event leading to death
0 0
Patients with any treatment-emergent
adverse event leading to permanent
treatment discontinuation
3 (5.5) 8 (14.0)
Treatment-emergent adverse event of
special interest
Congestive heart failure 2 (3.6) 3 (5.3)
Treatment-emergent adverse events
by primary system organ class
Gastrointestinal disorders 10 (18.2) 17 (29.8)
Respiratory, thoracic, and mediastinal
disorders
7 (12.7) 8 (14.0)
Nervous system disorders 6 (10.9) 7 (12.3)
Infections and infestations 8 (14.5) 6 (10.5)
Cardiac disorders 3 (5.5) 5 (8.8)
Metabolism and nutrition disorders 3 (5.5) 3 (5.3)
Vascular disorders 2 (3.6) 3 (5.3)
Psychiatric disorders 2 (3.6) 1 (1.8)
Eye disorders 1 (1.8) 1 (1.8)
Ear and labyrinth disorders 2 (3.6) 1 (1.8)
Skin and subcutaneous tissue disorders 2 (3.6) 1 (1.8)
Musculoskeletal and connective
tissue disorders
4 (7.3) 1 (1.8)
Renal and urinary disorders 1 (1.8) 1 (1.8)
Immune system disorders 1 (1.8) 0
Hepatobiliary disorders 1 (1.8) 0
All data are expressed as n (%). Treatment-emergent adverse events
include all patients randomized and that received at least one dose of
study drug
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over the 12-week duration of treatment. Safety findings were
consistent with the known profile of dronedarone.
Conflict of interest Michael D. Ezekowitz has served as a consultant to
and speaker for Boehringer Ingelheim, Ridgefield, CT, and as a consul-
tant to Pfizer, New York, NY; Sanofi-aventis US, Bridgewater, NJ;
Bristol-Myers Squibb, New York, NY; Portola Pharmaceuticals, Plumas
County, CA; Bayer, Pittsburgh, PA; Daiichi Sankyo, Parsippany, NJ;
Medtronic, Minneapolis, MN; Aegerion Pharmaceuticals, Cambridge,
MA; Merck, Whitehouse Station, NJ; Johnson & Johnson, New Bruns-
wick, NJ; Gilead Sciences, Inc., Foster City, CA; Janssen Scientific
Affairs, Titusville, NJ; Pozen Inc, Chapel Hill, NC; and CoherexMedical,
Salt Lake City, UT. Kenneth A. Ellenbogen has served as a consultant to
Pfizer. John P. DiMarco has received grant/research support from Gilead
Sciences, Inc., Sanofi-aventis US, has served as a consultant to Novartis
Pharmaceuticals Corp., East Hanover, NJ, and St. Jude Medical,
Secaucus, NJ, has received honoraria from Boston Scientific, Natick,
MA, and has served as an advisor to Medtronic. Karoly Kaszala has
served as a consultant to Sanofi-aventis US. Alexander Boddy and
Andrew Koren are employees of Sanofi-aventis US. Gregory Geba was
an employee of Sanofi-aventis US at the time this study was conducted.
Funding sources This study was funded by Sanofi-aventis US, Bridge-
water, NJ. Editorial support was provided by Peloton Advantage, LLC,
Parsippany, NJ, and Paulette Trent, funded by Sanofi-aventis US. The
opinions expressed in the current article are those of the authors. The
authors received no honorarium or other form of financial support related
to the development of this manuscript.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M.,
Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M.,
Furie, K. L., Heck, D. V., Johnston, S. C., Kasner, S. E., Kittner, S.
J., Mitchell, P. H., Rich, M. W., Richardson, D., Schwamm, L. H.,
Wilson, J. A., & on behalf of the American Heart Association Stroke
Council, Council on Cardiovascular and Stroke Nursing, Council on
Clinical Cardiology, and Council on Peripheral Vascular Disease.
(2014). Guidelines for the prevention of stroke in patients with stroke
and transient ischemic attack: a guideline for healthcare professionals
from the American Heart Association/American Stroke Association.
Stroke, 45, 2160–2236.
2. Gautier, P., Guillemare, E., Marion, A., Bertrand, J. P., Tourneur, Y.,
& Nisato, D. (2003). Electrophysiologic characterization of
dronedarone in guinea pig ventricular cells. Journal of
Cardiovascular Pharmacology, 41, 191–202.
3. Hodeige, D., Heyndrickx, J. P., Chatelain, P., & Manning, A. (1995).
SR 33589, a new amiodarone-like antiarrhythmic agent: anti-
adrenoceptor activity in anaesthetized and conscious dogs.
European Journal of Pharmacology, 279, 25–32.
4. Sun, W., Sarma, J. S., & Singh, B. N. (1999). Electrophysiological
effects of dronedarone (SR33589), a noniodinated benzofuran deriv-
ative, in the rabbit heart: comparison with amiodarone. Circulation,
100, 2276–2281.
5. Wegener, F. T., Ehrlich, J. R., & Hohnloser, S. H. (2006).
Dronedarone: an emerging agent with rhythm- and rate-controlling
effects. Journal of Cardiovascular Electrophysiology, 17(Suppl 2),
S17–S20.
6. (2012). Multaq [package insert]. Bridgewater, NJ: sanofi-aventis
U.S. LLC.
7. Hohnloser, S. H., Crijns, H. J., van Eickels, M., Gaudin, C., Page, R.
L., Torp-Pedersen, C., & Connolly, S. J. (2009). Effect of
dronedarone on cardiovascular events in atrial fibrillation. New
England Journal of Medicine, 360, 668–678.
8. Singh, B. N., Connolly, S. J., Crijns, H. J., Roy, D., Kowey, P. R.,
Capucci, A., Radzik, D., Aliot, E. M., & Hohnloser, S. H. (2007).
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or
flutter. New England Journal of Medicine, 357, 987–999.
9. (2008). Pacerone [package insert]. Minneapolis, MN: Upsher-Smith
Laboratories, Inc.
10. Krishnamoorthy, S., & Lip, G. Y. (2009). Antiarrhythmic drugs for
atrial fibrillation: focus on dronedarone. Expert Review of
Cardiovascular Therapy, 7, 473–481.
11. Wyse, D. G. (2004). Overview of endpoints in atrial fibrillation
studies. Heart Rhythm, 1, B3–7. discussion.
12. Camm, A. J., & Reiffel, J. A. (2008). Defining endpoints in clinical
trials on atrial fibrillation. European Heart Journal, 10(Suppl H),
H55–H78.
13. Pritchett, E. L. (2004). Symptomatic arrhythmia recurrence as an
outcome in clinical trials of antiarrhythmic drug therapy. Heart
Rhythm, 1, B36–B40.
14. Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris,
C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K.,
Lewis, H. D., Jr., Raisch, D. W., & Ezekowitz, M. D. (2005).
Amiodarone versus sotalol for atrial fibrillation. New England
Journal of Medicine, 352, 1861–1872.
15. Kaemmerer, W. F., Rose, M. S., & Mehra, R. (2001). Distribution of
patients’ paroxysmal atrial tachyarrhythmia episodes: implications
for detection of treatment efficacy. Journal of Cardiovascular
Electrophysiology, 12, 121–130.
16. Shehadeh, L. A., Liebovitch, L. S., &Wood, M. A. (2002). Temporal
patterns of atrial arrhythmia recurrences in patients with implantable
defibrillators: implications for assessing antiarrhythmic therapies.
Journal of Cardiovascular Electrophysiology, 13, 303–309.
17. Ezekowitz, M. D., Nagarakanti, R., Lubinski, A., Bandman, O.,
Canafax, D., Ellis, D. J., Milner, P. G., Ziola, M., Thibault, B., &
Hohnloser, S. H. (2012). A randomized trial of budiodarone in
paroxysmal atrial fibrillation. Journal of Interventional Cardiac
Electrophysiology, 34, 1–9.
18. Flaker, G. C., Belew, K., Beckman, K., Vidaillet, H., Kron, J., Safford,
R., Mickel, M., & Barrell, P. (2005). Asymptomatic atrial fibrillation:
demographic features and prognostic information from the Atrial
Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM) study. American Heart Journal, 149, 657–663.
19. Healey, J. S., Connolly, S. J., Gold,M. R., Israel, C.W., van Gelder, I.
C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., Morillo,
C. A., Carlson,M., Themeles, E., Kaufman, E. S., &Hohnloser, S. H.
(2012). Subclinical atrial fibrillation and the risk of stroke. New
England Journal of Medicine, 366, 120–129.
20. Gillis, A. M. (2004). Rhythm control in atrial fibrillation: endpoints
for device-based trials. Heart Rhythm, 1, B52–B57.
21. Euler, D. E., & Friedman, P. A. (2003). Atrial arrhythmia burden as
an endpoint in clinical trials: is it the best surrogate? Lessons from a
multicenter defibrillator trial. Cardiac Electrophysiology Review, 7,
355–358.
22. Gillis, A. M., & Morck, M. (2002). Atrial fibrillation after DDDR
pacemaker implanta t ion . Journal o f Cardiovascular
Electrophysiology, 13, 542–547.
23. Israel, C. W., Gronefeld, G., Ehrlich, J. R., Li, Y. G., & Hohnloser, S.
H. (2004). Long-term risk of recurrent atrial fibrillation as documented
by an implantable monitoring device: implications for optimal patient
care. Journal of the American College of Cardiology, 43, 47–52.
J Interv Card Electrophysiol (2015) 42:69–76 75
24. Padeletti, L., Santini, M., Boriani, G., Botto, G., Capucci, A., Gulizia,
M., Ricci, R., Spampinato, A., Pieragnoli, P., Warman, E., Vimercati,
M., & Grammatico, A. (2005). Temporal variability of atrial tachy-
arrhythmia burden in bradycardia-tachycardia syndrome patients.
European Heart Journal, 26, 165–172.
25. Mehra, R., Ziegler, P., & Koehler, J. (2004). Diagnostic information
in implantable devices that pertain to endpoints in atrial fibrillation
studies. Heart Rhythm, 1, B64–B69.
26. Carlson, M. D., Ip, J., Messenger, J., Beau, S., Kalbfleisch, S.,
Gervais, P., Cameron, D. A., Duran, A., Val-Mejias, J., Mackall, J.,
& Gold, M. (2003). A new pacemaker algorithm for the treatment of
atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing
Trial (ADOPT). Journal of the American College of Cardiology,
42, 627–633.
27. Friedman, P. A., Dijkman, B., Warman, E. N., Xia, H. A., Mehra, R.,
Stanton, M. S., & Hammill, S. C. (2001). Atrial therapies reduce
atrial arrhythmia burden in defibrillator patients. Circulation, 104,
1023–1028.
28. Gillis, A. M., Connolly, S. J., Lacombe, P., Philippon, F.,
Dubuc, M., Kerr, C. R., Yee, R., Rose, M. S., Newman, D.,
Kavanagh, K. M., Gardner, M. J., Kus, T., & Wyse, D. G.
(2000). Randomized crossover comparison of DDDR versus
VDD pacing after atrioventricular junction ablation for pre-
vention of atrial fibrillation. The atrial pacing peri-ablation for
paroxysmal atrial fibrillation (PA (3)) study investigators.
Circulation, 102, 736–741.
29. Lee, M. A., Weachter, R., Pollak, S., Kremers, M. S., Naik, A. M.,
Silverman, R., Tuzi, J., Wang, W., Johnson, L. J., & Euler, D. E.
(2003). The effect of atrial pacing therapies on atrial tachyarrhythmia
burden and frequency: results of a randomized trial in patients with
bradycardia and atrial tachyarrhythmias. Journal of the American
College of Cardiology, 41, 1926–1932.
76 J Interv Card Electrophysiol (2015) 42:69–76
